Selected passages from the FDA letter
Quoted FDA text from the published dataset. These selected excerpts are not the complete letter.
Passage 1The compounded semaglutide products displayed on your website identify “Peak Now” on the pictured label, suggesting Peak Now is the compounder of those drugs when in fact it is not.
Passage 2Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.
Passage 3This FDA-approved treatment promotes safe, effective weight loss, helping you reduce up to 20% of your body weight and maintain long-term results.
Passage 4Clinically proven to aid in significant weight loss in overweight adults.
Passage 5Safe, affordable, and effective.
Passage 6The compounded products offered on PeaksCurative.com use FDA approved active pharmaceutical ingredients (API).
Passage 7Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.
Passage 8The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)].
Citations in the original letter
As cited in this historical letter, not a statement of current regulatory requirements.
- 21 CFR 201.1(h)(2)
- 21 CFR 201.1(a)